INVO Fertility, Inc. (IVF): Nasdaq/NYSE listing notice — INVO Bioscience receives Nasdaq delisting notice for failure to meet $2.5M equity minimum

INVO Fertility, Inc.

Nasdaq notified INVO on May 23, 2023, of non-compliance with Listing Rule 5550(b)(1) requiring $2.5M stockholders' equity.
Company failed to regain compliance by the May 22, 2023 extension deadline.
INVO plans to request a hearing before the Nasdaq Hearings Panel to stay delisting.
No assurance that the Panel will grant continued listing or an extension.
Stockholders' equity deficiency triggers potential delisting from Nasdaq Global Market.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

May 23, 2023, INVO Bioscience, Inc. (the “Company”) was notified by the Listing Qualifications department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the $2.5 million stockholders’ equity requirement for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Rule”), as of May 22, 2023, the Company’s common stock was subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing be

View on SEC.gov

19 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

INVO Fertility, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-019455

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.